Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

A correction has been published 1

Correspondence

Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Ibrutinib, a Bruton's tyrosine kinase inhibitor, is active in CLL, but resistance may emerge. The authors observed the emergence of a CLL clone with a cysteine-to-serine change in amino acid 481 of the target protein that substantially weakens drug binding and leads to resistance.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Richard R. Furman, M.D.
Shuhua Cheng, Ph.D.
Weill Cornell Medical College, New York, NY

Pin Lu, M.D., Ph.D.
University of Chicago, Chicago, IL

Menu Setty, M.S.
Alexendar R. Perez, B.A.
Memorial Sloan-Kettering Cancer Center, New York, NY

Ailin Guo, M.D., Ph.D.
University of Chicago, Chicago, IL

Joelle Racchumi, B.S.
Weill Cornell Medical College, New York, NY

Guozhou Xu, Ph.D.
Hao Wu, Ph.D.
Boston Children's Hospital, Boston, MA

Jiao Ma, Ph.D.
Weill Cornell Medical College, New York, NY

Susanne M. Steggerda, Ph.D.
Pharmacyclics, Sunnyvale, CA

Morton Coleman, M.D.
Weill Cornell Medical College, New York, NY

Christina Leslie, Ph.D.
Memorial Sloan-Kettering Cancer Center, New York, NY

Y. Lynn Wang, M.D., Ph.D.
University of Chicago, Chicago, IL

Funding and Disclosures

Drs. Furman, Cheng, and Lu contributed equally to this letter.

Supported by grants from the Leukemia and Lymphoma Society and the Prince Family Foundation (both to Dr. Wang).

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

This letter was published on May 28, 2014, and updated on June 6, 2014, at NEJM.org.

Print Subscriber? Activate your online access.